A Stakeholder Interchange convened in Los Angeles, California, by The American Journal of Managed Care explores the treatment ...

The U.S. Food and Drug Administration has approved Darzalex Faspro (daratumumab and hyaluronidase-fihj) as a single-agent ...

For the first time, patients with abnormal cells detected in their bone marrow have a treatment option before the condition ...

For the first time in more than a decade, a new frontline treatment for an incurable blood cancer is being added to the ...

Sequencing treatment for patients with relapsed or refractory multiple myeloma depends on the patient’s disease and history, explained Lisa Hwa Christenson, DNP, APRN, CNP, associate professor of ...

"Medical Journeys" is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this 12-part journey through a disease state ...

MM survival rates have improved with the introduction of novel agents. Treatment of MM within the first year is associated with improved survival. New research has concluded that, despite more ...

Maintenance therapy is given after initial treatment for multiple myeloma. It aims to control your cancer and prevent progression. The type of maintenance therapy you receive depends on whether your ...

In patients with symptomatic multiple myeloma, renal impairment leading to acute kidney injury (AKI) is a common complication ...